Clindamycin and Toxin Binder Dosing
When using bile acid sequestrants (cholestyramine, colestipol, or colesevelam) as toxin binders, administer other medications—including clindamycin—at least 1 hour before or 4-6 hours after the resin to avoid impeding drug absorption.
Timing Strategy to Prevent Drug-Resin Interaction
The critical issue with bile acid sequestrants is their non-selective binding of medications in the gastrointestinal tract. Based on FDA labeling and guideline evidence:
Recommended Separation Intervals
- Standard approach: Give clindamycin at least 1 hour before or 4-6 hours after cholestyramine/colestipol 1
- Optimal separation: The 4-6 hour interval after the resin provides maximum protection against binding 1
- Colesevelam: Similar timing applies—other medications should be given at least 4 hours before this bile acid sequestrant 2
Practical Dosing Schedule
If a patient requires both clindamycin and a toxin binder:
- Morning dose: Administer clindamycin first
- Wait 1+ hours: Then give the bile acid sequestrant with breakfast
- Afternoon/evening doses: Give clindamycin 4-6 hours after the resin dose
- Alternative: Give the resin, wait 4-6 hours, then administer clindamycin
Context: Clindamycin Dosing
For reference, standard clindamycin dosing (when not considering resin interactions):
- Oral pediatric: 30-40 mg/kg/day divided into 3-4 doses 3, 4, 3
- IV pediatric: 40 mg/kg/day divided every 6-8 hours 3, 4, 3
- Adult oral: 300-450 mg three times daily 5
- Adult IV: 600 mg every 8 hours 5
Important Caveats
The 3-hour separation may be insufficient for drugs with enterohepatic recirculation. Research demonstrates that even 3-hour staggering failed to prevent cholestyramine interaction with sulindac, which undergoes enterohepatic recycling 6. While clindamycin doesn't have significant enterohepatic circulation like sulindac, the safest approach remains the 4-6 hour separation recommended in FDA labeling.
Monitor clinical response closely when combining these agents, as even with appropriate timing, some reduction in bioavailability may occur. Research shows cholestyramine reduced valproate AUC by 14% even with 3-hour separation 7, and reduced ibuprofen AUC by 26% with concurrent dosing 8.
Consider alternative toxin management strategies if feasible, as the dosing complexity increases medication errors and non-adherence. The evidence for cholestyramine as a toxin binder in C. difficile infection is limited 9, though it has shown promise in preventing antibiotic resistance emergence in gut flora 10.